

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A pharmaceutical composition comprising, in admixture, a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives, and a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof,
wherein the first active ingredient and the second active ingredient are the only active ingredients present in the composition a histamine receptor antagonist and its pharmaceutically acceptable derivatives.
2. (Currently amended) [[A]] The pharmaceutical composition according to claim 1, wherein the first and/or second active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] in the form of a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a

~~salt, solvate of a salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.~~

3. – 16. (Cancelled)

17. (Currently amended) A pharmaceutical product comprising, in combination, a preparation of a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives, and a preparation of a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof a histamine receptor antagonist and its pharmaceutically acceptable derivatives, for simultaneous, sequential or separate use in therapy.

wherein the first active ingredient and the second active ingredient are the only active ingredients present in the pharmaceutical product.

18. (Currently amended) **[[A]]** The pharmaceutical product according to claim 17, wherein the first and/or second active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] in

~~the form of a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt, solvate of a salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.~~

19. – 27. (Cancelled)

28. (Currently amended) A kit comprising a preparation of a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives, a preparation of a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof a histamine receptor antagonist and its pharmaceutically acceptable derivatives, and instructions for simultaneous, sequential or separate administration to the patient in need thereof,
wherein the first active ingredient and the second active ingredient are the only active ingredients present in the pharmaceutical product.

29. (Currently amended) **[[A]]** The kit according to claim 28, wherein the first and/or second active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] in the form of a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt, solvate of a salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.

30. – 47. (Cancelled)